Biotech Values

[rkrw]

Thanks for the detailed reply. After the outcome it will all make sense

Noticed the Moffitt data excluded patients who didn't take iressa for >12 weeks. 1 year survival of 35% is slightly better than BR21, but that excludes the early dropouts. In a real trial, the fda certainly would want to know their outcomes